Exscientia
NASDAQ:EXAIExscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
GuestLogix
TSE:GXIGuestLogix Inc. is a retailing and payment technology company. The Company offers a portfolio of hardware, software, content and professional services to travel operators across the world. The Company's segments include GuestLogix Onboard and OpenJaw. Its segments are engaged in providing merchandising, payment and business intelligence technology delivered to the passenger travel industry, both onboard and off-board. The Company focuses on providing retail technology that supports both the travel retail and ancillary revenue programs of the travel industry, such as the sale of onboard food and beverage, duty-free products, onboard entertainment (digital content), seat upgrades and ground ancillaries, such as hotels, car rentals and destination-content. It also serves clients using its retail systems to sell core product offerings, such as airline and rail tickets. Its network spans over 144 countries across the Americas, Europe, the Middle East and Africa (EMEA) and Asia Pacific.
Magellan Health
NASDAQ:MGLNMagellan Health, Inc. engages in the business of healthcare management. It operates through the following segments: Healthcare, Pharmacy Management and Corporate. The Healthcare segment includes the Behavioral & Specialty Health reporting unit, which provides carve-out management services for behavioral health, employee assistance plans, and other areas of specialty healthcare. The Pharmacy Management segment comprises of services that provide clinical and financial management of pharmaceuticals paid under both the medical and the pharmacy benefit. The Corporate segment covers amounts not allocated to the Healthcare and Pharmacy Management segments. The company was founded in 1969 and is headquartered in Phoenix, AZ.
NuVasive
NASDAQ:NUVANuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Olink Holding AB (publ)
NASDAQ:OLKOlink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, the company provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden.